S. Guo

Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance

Yuhui Huang, Yanhua Yue, Tong-bing Chen, 2022, Frontiers in Oncology.

Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy.

Yuhui Huang, Yanhua Yue, Feng Li, 2022, Leukemia research.

Vascular Normalization Was Associated with Colorectal Tumor Regression upon Anti-PD-L1 Combinational Therapy

S. Qin, Yuhui Huang, Yanhua Yue, 2023, Journal of immunology research.

P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY

A. Oriol, A. Larocca, K. Weisel, 2022, HemaSphere.